Nordazepam API Manufacturers

compare suppliers & get competitive offers

Pharmaoffer_donkere_achtergrond
No suppliers found
Sorry, there are currently no suppliers listed for this ingredient. Hopefully we can help you with other ingredients.
Notify me!
Want to be the first to find out when a supplier for Nordazepam is listed?

Join our notification list by following this page.

List your company
Are you a supplier of Nordazepam or other APIs and are you looking to list your company on Pharmaoffer?

Click the button below to find out more

Find CDMO
Looking for a CDMO/CMO that can help you with your pharmaceutical needs?

Click the button below to switch over to the contract services area of Pharmaoffer.

Looking for Nordazepam API 1088-11-5?

Description:
Here you will find a list of producers, manufacturers and distributors of Nordazepam. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
API | Excipient name:
Nordazepam 
Synonyms:
Desmethyldiazepam , N-desmethyldiazepam , Nordazepam CIV , Nordazepamum , Nordiazepam  
Cas Number:
1088-11-5 
DrugBank number:
DB14028 
Unique Ingredient Identifier:
67220MCM01

General Description:

Nordazepam, identified by CAS number 1088-11-5, is a notable compound with significant therapeutic applications. An intermediate in the metabolism of DIAZEPAM to OXAZEPAM. It may have actions similar to those of diazepam.

Classification:

Nordazepam belongs to the class of organic compounds known as 1,4-benzodiazepines. These are organic compounds containing a benzene ring fused to a 1,4-azepine, classified under the direct parent group 1,4-benzodiazepines. This compound is a part of the Organic compounds, falling under the Organoheterocyclic compounds superclass, and categorized within the Benzodiazepines class, specifically within the 1,4-benzodiazepines subclass.

Categories:

Nordazepam is categorized under the following therapeutic classes: Amino Acids, Amino Acids, Aromatic, Amino Acids, Cyclic, Amino Acids, Peptides, and Proteins, Anti-Anxiety Agents, Benzazepines, Benzodiazepines and benzodiazepine derivatives, Benzodiazepinones, Central Nervous System Agents, Central Nervous System Depressants, GABA Agents, GABA Modulators, Heterocyclic Compounds, Fused-Ring, Nervous System, Neurotransmitter Agents, Psycholeptics, Psychotropic Drugs, Tranquilizing Agents. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.

Nordazepam is a type of Central Nervous System Agents


Central Nervous System (CNS) Agents are a crucial category of pharmaceutical Active Pharmaceutical Ingredients (APIs) that specifically target the central nervous system. The CNS encompasses the brain and spinal cord, playing a vital role in regulating and controlling various bodily functions, including cognition, movement, emotions, and sensory perception. These agents are designed to interact with specific receptors, enzymes, or ion channels within the CNS to modulate neural activity and restore normal functioning.

CNS agents comprise a diverse range of pharmaceutical APIs, including analgesics, anesthetics, antipsychotics, sedatives, hypnotics, anti-epileptics, and antidepressants. Each subcategory addresses distinct neurological disorders and conditions. For instance, analgesics alleviate pain by targeting receptors in the brain and spinal cord, while antipsychotics are employed to manage psychosis symptoms in mental illnesses such as schizophrenia.

The development of CNS agents involves rigorous research, molecular modeling, and extensive clinical trials to ensure safety, efficacy, and specific target engagement. Pharmaceutical companies invest significant resources in identifying novel drug targets, synthesizing new compounds, and optimizing their pharmacological properties. These agents undergo rigorous regulatory evaluations and must adhere to stringent quality standards and guidelines.

Given the prevalence of CNS disorders globally, the market demand for effective CNS agents is substantial. The development of innovative CNS APIs not only improves patient outcomes but also provides valuable commercial opportunities for pharmaceutical companies. Continued advancements in CNS agent research and development hold the promise of groundbreaking therapies that can improve the quality of life for individuals affected by neurological conditions.